Data / Drug companies / Poly Pharmaceuticals, Inc.
Poly Pharmaceuticals, Inc.: 18 products in the FDA NDC directory, labeler code 50991
Updated November 6, 2026. Source: US Food and Drug Administration, National Drug Code Directory (openFDA).
Poly Pharmaceuticals, Inc. (labeler code 50991) lists 18 products in the FDA National Drug Code Directory, covering 15 finished drugs by generic name. By type: 16 over the counter drugs, 2 prescription drugs. Its main marketing category is over the counter monograph drugs. The newest product started marketing on April 23, 2026.
The request: Watch Poly Pharmaceuticals, Inc. (FDA labeler code 50991): each new product listing and each discontinued product. $10 of work on sign-up, no card.
SpecStream is the live web data engine for teams and agents. It reads the National Drug Code Directory that FDA publishes, and this page is that reading. Ask for the companies that make a drug, a class or a dosage form, with their headquarters, website and size added from the web, and new listings and discontinued products arrive in your sheet, CRM, Slack or agent as FDA posts them.
- Labeler code
- 50991
- Products in commercial distribution
- 18
- Packages
- 36
- Finished drugs by generic name
- 15
- Prescription products
- 2
- Over the counter products
- 16
- Controlled substance products
- Schedule V 1
- Flagged as original packager
- 18 of 18 products that carry the flag
- Started marketing in the last 12 months
- 1
- Earliest marketing start
- August 22, 2011
- openFDA record search
- api.fda.gov
Products by marketing category
Share of the company's products in commercial distribution.
| Marketing category | Products | Share |
|---|---|---|
| Over the counter monograph drugs | 16 | 88.9% |
| Generic drugs (ANDA) | 2 | 11.1% |
Products by type
| Type | Products | Share |
|---|---|---|
| Over the counter drugs | 16 | 88.9% |
| Prescription drugs | 2 | 11.1% |
Drugs it lists
Finished drugs by generic name, with how many companies list each.
| Drug | Products | Companies listing it |
|---|---|---|
| Dextromethorphan hbr, phenylephrine hcl, pyrilamine maleate | 1 | 1 |
| Dexchlorpheniramine maleate and dextromethorphan hbr | 1 | 1 |
| Dextromethorphan hbr, pheniramine maleate, phenylephrine hcl | 1 | 1 |
| Dexbrompheniramine maleate | 1 | 1 |
| Dexbrompheniramine maleate, pseudoephedrine hcl | 1 | 2 |
| Guaifenesin and pseudoephedrine hcl | 1 | 14 |
| Dextromethorphan hbr, guaifenesin and pseudoephedrine hcl | 1 | 1 |
| Pheniramine maleate, phenylephrine hcl | 1 | 1 |
| Triprolidine hcl, dextromethorphan hbr | 1 | 1 |
| Codeine phosphate, dexbrompheniramine maleate | 1 | 1 |
| Tolmetin sodium | 1 | 5 |
| Doxylamine succinate and phenylephrine hydrochloride | 1 | 1 |
| Dexbrompheniramine maleate, phenylephrine hydrochloride | 1 | 1 |
| Orphenadrine citrate, aspirin and caffeine | 1 | 3 |
| Guaifenesin and phenylephrine hcl | 1 | 2 |
Dosage forms
| Dosage form | Products | Share |
|---|---|---|
| Tablet | 10 | 55.6% |
| Liquid | 5 | 27.8% |
| Syrup | 1 | 5.6% |
| Tablet, film coated | 1 | 5.6% |
| Tablet, multilayer | 1 | 5.6% |
Pharmacologic classes
FDA established pharmacologic classes of its products.
Newest products
By marketing start date.
| Product | Product NDC | Dosage form | Marketing category | Marketing start |
|---|---|---|---|---|
| Poly-hist dm | 50991-271 | Liquid | Over the counter monograph drugs | April 23, 2026 |
| Duratuss dm | 50991-142 | Liquid | Over the counter monograph drugs | October 15, 2025 |
| Duratuss AC | 50991-540 | Liquid | Over the counter monograph drugs | September 8, 2025 |
| Durahist | 50991-865 | Tablet | Over the counter monograph drugs | April 22, 2025 |
| Tolectin | 50991-988 | Tablet, film coated | Generic drugs (ANDA) | April 4, 2024 |
| Alahist dm | 50991-444 | Liquid | Over the counter monograph drugs | June 8, 2023 |
| Polytussin DM | 50991-132 | Syrup | Over the counter monograph drugs | June 8, 2023 |
| Endal | 50991-136 | Liquid | Over the counter monograph drugs | May 22, 2023 |
| Alahist PE | 50991-788 | Tablet | Over the counter monograph drugs | August 24, 2020 |
| Alahist D | 50991-776 | Tablet | Over the counter monograph drugs | April 1, 2020 |
| Deconex dmx | 50991-740 | Tablet | Over the counter monograph drugs | June 1, 2019 |
| Poly Hist Forte | 50991-626 | Tablet | Over the counter monograph drugs | June 1, 2019 |
| Norgesic Forte | 50991-999 | Tablet, multilayer | Generic drugs (ANDA) | April 1, 2019 |
| Deconex IR | 50991-736 | Tablet | Over the counter monograph drugs | August 8, 2016 |
| Duraflu | 50991-535 | Tablet | Over the counter monograph drugs | October 1, 2015 |
| Poly-Vent DM | 50991-214 | Tablet | Over the counter monograph drugs | June 17, 2013 |
| Poly-Vent IR | 50991-212 | Tablet | Over the counter monograph drugs | June 11, 2013 |
| Ala-hist ir | 50991-783 | Tablet | Over the counter monograph drugs | August 22, 2011 |
CC0 1.0 public domain dedication (openFDA). Counts are products in the FDA National Drug Code Directory on November 6, 2026: 138,262 products in commercial distribution, meaning without a marketing end date in the past. A company is a labeler code; one company can hold several codes, and the directory carries no address. Inclusion in the directory is not FDA approval, and the marketing category says under which kind of application or rule a product is sold. This page uses openFDA data and is not endorsed or certified by FDA. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.